Posted by Michael Wonder on 28 Jul 2025
Imfinzi granted priority review and breakthrough therapy designation in the US for patients with resectable early-stage gastric and gastro-oesophageal junction cancers
28 July 2025 - Based on MATTERHORN Phase 3 trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit.
AstraZeneca’s supplemental biologics license application for Imfinzi (durvalumab) has been accepted and granted priority review in the US for the treatment of patients with resectable, early-stage and locally advanced (stages II, III, IVA) gastric and gastro-oesophageal junction cancers.
